Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 1
2023 1
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Sezgin Goksu S, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators. Cheng Y, et al. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. N Engl J Med. 2024. PMID: 39268857 Clinical Trial.
Natural Compounds of Salvia L. Genus and Molecular Mechanism of Their Biological Activity.
Zhumaliyeva G, Zhussupova A, Zhusupova GE, Błońska-Sikora E, Cerreto A, Omirbekova N, Zhunusbayeva Z, Gemejiyeva N, Ramazanova M, Wrzosek M, Ross SA. Zhumaliyeva G, et al. Among authors: ramazanova m. Biomedicines. 2023 Nov 27;11(12):3151. doi: 10.3390/biomedicines11123151. Biomedicines. 2023. PMID: 38137372 Free PMC article. Review.
Ego4D: Around the World in 3,600 Hours of Egocentric Video.
Grauman K, Westbury A, Byrne E, Cartillier V, Chavis Z, Furnari A, Girdhar R, Hamburger J, Jiang H, Kukreja D, Liu M, Liu X, Martin M, Nagarajan T, Radosavovic I, Ramakrishnan SK, Ryan F, Sharma J, Wray M, Xu M, Xu EZ, Zhao C, Bansal S, Batra D, Crane S, Do T, Doulaty M, Erapalli A, Feichtenhofer C, Fragomeni A, Fu Q, Gebreselasie A, Gonzalez C, Hillis J, Huang X, Huang Y, Jia W, Khoo W, Kolar J, Kottur S, Kumar A, Landini F, Li C, Li Y, Li Z, Mangalam K, Modhugu R, Munro J, Murrell T, Nishiyasu T, Price W, Ruiz Puentes P, Ramazanova M, Sari L, Somasundaram K, Southerland A, Sugano Y, Tao R, Vo M, Wang Y, Wu X, Yagi T, Zhao Z, Zhu Y, Arbelaez P, Crandall D, Damen D, Farinella GM, Fuegen C, Ghanem B, Krishna V, Jawahar CV, Joo H, Kitani K, Li H, Newcombe R, Oliva A, Park HS, Rehg JM, Sato Y, Shi J, Zheng Shou M, Torralba A, Torresani L, Yan M, Malik J. Grauman K, et al. Among authors: ramazanova m. IEEE Trans Pattern Anal Mach Intell. 2025 Nov;47(11):9468-9509. doi: 10.1109/TPAMI.2024.3381075. IEEE Trans Pattern Anal Mach Intell. 2025. PMID: 39058617
Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I, Borisov P, Abdelgafur A, Leonenkov R, Novikova O, Guseva I, Demchenkova M, Mikhailova N, Semenov A, Yurmazov Z, Sivunova I, Ramazanova M, Gamayunov S, Kosov D, Bratslavsky G. Tsimafeyeu I, et al. Among authors: ramazanova m. Target Oncol. 2019 Feb;14(1):33-38. doi: 10.1007/s11523-018-0613-y. Target Oncol. 2019. PMID: 30607698 Clinical Trial.